[ Harpoon Therapeutics raises $45M in Series B ]

Harpoon Therapeutics has raised $45 million in Series B funding.

Founded in 2015, Harpoon Therapeutics is a biotechnology company developing novel T-cell recruiting biologic therapies for the treatment of cancer.

Proceeds from the financing will be used to advance Harpoon Therapeutics’ novel, proprietary, tri-specific T-cell activating construct (TriTAC™) immuno-oncology platform, including moving two lead programs into clinical trials and expanding the product pipeline through discovery and partnering initiatives.

Funding  Series B
Founded  2015
Country  USA
City   San Francisco
Founder / CEO  Gerald McMahon
Deal Size  $45M
Investors  MPM Capital
 Arix Bioscience
 New Leaf Venture Partners
 Taiho Ventures
Previous Investors  MPM Capital